REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T.

Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares

Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q2 2019 Results - Earnings Call Transcript

Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $742,350 of Shares

Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?

As a leading gene therapy innovator, Regenxbio is undergoing many strong fundamental developments.

Regenxbio: More To Come After Zolgensma Approval

Regenxbio expects to obtain royalty payments from Novartis for Zolgensma after it was approved by the FDA to treat patients with spinal muscular atrophy.

With FDA Approval Of Zolgensma, Regenxbio Sets Out For First Revenue Stream

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%

Novartis

A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.

Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio

Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q1 2019 Results - Earnings Call Transcript

As lucrative investments, gene therapy companies also are delivering hope for countless patients worldwide.

Regenxbio: A Stellar Gene Therapy Innovator With Multiple Upsides

A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday.

A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock

bluebird bio

Bristol-Myers

Celgene

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Genomic Health

Gilead Sciences

Illumina

Myriad Genetics

Invitae

Spark Therapeutics

Pacific Biosciences of California

Roche Holding AG

Thermo Fisher Scientific

These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.

Top Gene-Sequencing Stocks for 2019

Audentes Therapeutics

uniQure

Solid Biosciences

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Blueprint Medicines

Evolus

These under-the-radar stocks could be poised to make big moves in the coming months.

3 Small-Cap Biotech Stocks to Watch Now

News for REGENXBIO Stock (RGNX)